Endorsed By

ForeseeHome is a home-based monitoring program for intermediate dry AMD patients to detect wet AMD earlier1

FDA cleared and covered by Medicare and most private insurance






Common intermediate dry AMD patient types

Intermediate dry AMD with 1 large drusen (≥125 μm)

Intermediate dry AMD with multiple medium drusen
(63 – 124 μm) in both eyes

Intermediate dry AMD with drusen and hyper pigmentation

Intermediate dry AMD in one eye, wet AMD or central GA in the fellow eye

Patients must have:

OD (right eye)
H 35.31 1 2
(dry intermediate, right eye)
BCVA 20/60 or better

OS (left eye)
H 35.31 2 2
(dry intermediate, left eye)
BCVA 20/60 or better

H 35.31 3 2
(dry intermediate, bilateral)
BCVA 20/60 or better

  • For these patients, recommend ForeseeHome to help ensure wet AMD conversion is detected as early as possible

AMD=age-related macular degeneration; BCVA=best corrected visual acuity; GA=geographic atrophy.

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The technical component of the ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD. Please refer to your local Medicare Administrative Contractor (MAC) for which the ordering physician resides concerning coverage availability for the physician professional services component of the test.